Dror Bashan - 25 Feb 2022 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Reporting relationship: President and CEO, Director
Issuer ticker: PLX
Reported as of: 25 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Feb 2022, 16:01:13 UTC
Next SEC filing: 13 Apr 2022
Source filing: View source filing
Reporting owner signature: /s/ Dror Bashan

Key filing fact

Dror Bashan filed Form 4 for Protalix BioTherapeutics, Inc. (PLX) on 28 Feb 2022.

Key facts

This page summarizes Dror Bashan's Form 4 filing for Protalix BioTherapeutics, Inc. (PLX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 28 Feb 2022, 16:01.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PLX transaction

Common Stock

Award

Transaction value
Shares: +637,531
Change %: +142%
Price
Shares after: 1,085,458
Date: 25 Feb 2022
Ownership: By Trust
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020.

Footnote F2

To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.